This study using mice demonstrates the effectiveness of simultaneous simple suspensions of CBM and antibiotics in treating CDI. This approach significantly reduces C. difficile counts, modulates cytokine levels, and maintains probiotic viability, potentially making it a viable option for administration via gastric tubes in clinical settings.

5 months ago

Preclinical • Journal

IFNG (Interferon, gamma) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL10 (Interleukin 10)

Cdactin-O (CBM588)

5ms

Adding a Probiotic (CBM588) to Pembrolizumab for the Treatment of Renal Cell Cancer After Surgery (clinicaltrials.gov)

P2, N=62, Not yet recruiting, City of Hope Medical Center

5 months ago

New P2 trial

CXCL8 (Chemokine (C-X-C motif) ligand 8)

Keytruda (pembrolizumab) • Cdactin-O (CBM588)

6ms

The Protective Effects of Lactobacillus reuteri Combined With Clostridium butyricum Miyairi 588 on Intestinal Barrier Function, Water Transport, and Oxidative Stress in a Rat Model of 5FU-Induced Diarrhea. (PubMed, Food Sci Nutr)

5-Fluorouracil (5FU) is a commonly employed and highly effective chemotherapeutic agent in clinical oncology. LCs also notably diminished the mRNA expression levels of AQP7, VIP, and PKA. This study demonstrates that LCs have therapeutic effects on colitis, primarily through their antioxidant properties, anti-apoptotic effects, mucosal barrier integrity maintenance, neutrophil infiltration reduction, and inflammatory cytokines and aquaporin expression modulation.

6 months ago

Preclinical • Journal

AKT1 (V-akt murine thymoma viral oncogene homolog 1) • IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • NFKB1 (Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1) • CASP3 (Caspase 3) • IL1B (Interleukin 1, beta) • VCAM1 (Vascular Cell Adhesion Molecule 1) • OCLN (Occludin)

5-fluorouracil • Cdactin-O (CBM588)

7ms

CBM588 in Improving Clinical Outcomes in Patients Who Have Undergone Donor Hematopoietic Stem Cell Transplant (clinicaltrials.gov)

P1, N=36, Active, not recruiting, City of Hope Medical Center | Trial completion date: Apr 2025 --> Mar 2026 | Trial primary completion date: Apr 2025 --> Mar 2026

7 months ago

Trial completion date • Trial primary completion date

Cdactin-O (CBM588)

9ms

PROREDI: Study to Evaluate the Treatment Benefits of Probiotic Clostridium Butyricum CBM588® for IBS-D (clinicaltrials.gov)

P=N/A, N=400, Completed, Liaquat University of Medical & Health Sciences | Trial completion date: Sep 2024 --> Mar 2025 | Initiation date: Sep 2023 --> Nov 2024 | Trial primary completion date: Mar 2024 --> Feb 2025

9 months ago

Trial completion date • Trial initiation date • Trial primary completion date • HEOR

Cdactin-O (CBM588)

9ms

PROREDI: Study to Evaluate the Treatment Benefits of Probiotic Clostridium Butyricum CBM588® for IBS-D (clinicaltrials.gov)

P=N/A, N=400, Completed, Liaquat University of Medical & Health Sciences | N=200 --> 400

9 months ago

Enrollment change • HEOR

Cdactin-O (CBM588)

9ms

CBM588 Reduces Colorectal Polyp Recurrence (clinicaltrials.gov)

P=N/A, N=500, Enrolling by invitation, Kaohsiung Medical University

9 months ago

New trial

Cdactin-O (CBM588)

9ms

CBM588 in Improving Clinical Outcomes in Patients Who Have Undergone Donor Hematopoietic Stem Cell Transplant (clinicaltrials.gov)

P1, N=36, Active, not recruiting, City of Hope Medical Center | Trial completion date: Dec 2024 --> Apr 2025 | Trial primary completion date: Dec 2024 --> Apr 2025

9 months ago

Trial completion date • Trial primary completion date

TNFA (Tumor Necrosis Factor-Alpha) • TNFRSF1A (TNF Receptor Superfamily Member 1A) • TGFB1 (Transforming Growth Factor Beta 1)

Cdactin-O (CBM588)

1year

CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney Cancer (clinicaltrials.gov)

P1, N=31, Active, not recruiting, City of Hope Medical Center | Trial completion date: Oct 2024 --> Oct 2025 | Trial primary completion date: Oct 2024 --> Oct 2025

1 year ago

Trial completion date • Trial primary completion date • Combination therapy • Metastases

Opdivo (nivolumab) • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule) • Cdactin-O (CBM588)

1year

PROREDI: Study to Evaluate the Treatment Benefits of Probiotic Clostridium Butyricum CBM588® for IBS-D (clinicaltrials.gov)

P=N/A, N=200, Completed, Liaquat University of Medical & Health Sciences

1 year ago

New trial • HEOR

Cdactin-O (CBM588)

over1year

P30CA033572: CBM588, Nivolumab, and Ipilimumab in Treating Patients With Stage IV or Advanced Kidney Cancer (clinicaltrials.gov)

P1, N=30, Completed, City of Hope Medical Center | Active, not recruiting --> Completed | Trial completion date: Jun 2024 --> Dec 2023 | Trial primary completion date: Jun 2024 --> Dec 2023

over 1 year ago

Trial completion • Trial completion date • Trial primary completion date • Combination therapy • Metastases

IL6 (Interleukin 6) • CXCL8 (Chemokine (C-X-C motif) ligand 8)

Opdivo (nivolumab) • Yervoy (ipilimumab) • Cdactin-O (CBM588)

over1year

Cabozantinib and nivolumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial. (PubMed, Nat Med)

Supplementation with CBM588, a bifidogenic live bacterial product, has been associated with improved clinical outcomes in persons with metastatic renal cell carcinoma (mRCC) receiving nivolumab and ipilimumab...Our results provide a preliminary signal of improved clinical activity with CBM588 in treatment-naive participants with mRCC receiving cabozantinib and nivolumab. Further investigation is needed to confirm these findings and better characterize the underlying mechanism driving this effect.ClinicalTrials.gov identifier: NCT05122546.

over 1 year ago

P1 data • Journal • Metastases

AXL (AXL Receptor Tyrosine Kinase)

Opdivo (nivolumab) • Yervoy (ipilimumab) • Cabometyx (cabozantinib tablet) • Cdactin-O (CBM588)